PT2922530T - Formulações de acetato de caspofungina - Google Patents

Formulações de acetato de caspofungina

Info

Publication number
PT2922530T
PT2922530T PT128105194T PT12810519T PT2922530T PT 2922530 T PT2922530 T PT 2922530T PT 128105194 T PT128105194 T PT 128105194T PT 12810519 T PT12810519 T PT 12810519T PT 2922530 T PT2922530 T PT 2922530T
Authority
PT
Portugal
Prior art keywords
caspofungin acetate
acetate formulations
formulations
caspofungin
acetate
Prior art date
Application number
PT128105194T
Other languages
English (en)
Inventor
Jiang Zhi-Qiang
Usayapant Arunya
Bowman David
Kwok Keith
Peterson Joel
Original Assignee
Fresenius Kabi Usa Llc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Fresenius Kabi Usa Llc filed Critical Fresenius Kabi Usa Llc
Publication of PT2922530T publication Critical patent/PT2922530T/pt

Links

Classifications

    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/16Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing nitrogen, e.g. nitro-, nitroso-, azo-compounds, nitriles, cyanates
    • A61K47/18Amines; Amides; Ureas; Quaternary ammonium compounds; Amino acids; Oligopeptides having up to five amino acids
    • A61K47/183Amino acids, e.g. glycine, EDTA or aspartame
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/185Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
    • A61K31/19Carboxylic acids, e.g. valproic acid
    • A61K31/195Carboxylic acids, e.g. valproic acid having an amino group
    • A61K31/197Carboxylic acids, e.g. valproic acid having an amino group the amino and the carboxyl groups being attached to the same acyclic carbon chain, e.g. gamma-aminobutyric acid [GABA], beta-alanine, epsilon-aminocaproic acid or pantothenic acid
    • A61K31/198Alpha-amino acids, e.g. alanine or edetic acid [EDTA]
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00Medicinal preparations containing peptides
    • A61K38/04Peptides having up to 20 amino acids in a fully defined sequence; Derivatives thereof
    • A61K38/12Cyclic peptides, e.g. bacitracins; Polymyxins; Gramicidins S, C; Tyrocidins A, B or C
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/20Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing sulfur, e.g. dimethyl sulfoxide [DMSO], docusate, sodium lauryl sulfate or aminosulfonic acids
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00Medicinal preparations characterised by special physical form
    • A61K9/0012Galenical forms characterised by the site of application
    • A61K9/0019Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00Medicinal preparations characterised by special physical form
    • A61K9/14Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/19Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles lyophilised, i.e. freeze-dried, solutions or dispersions

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Public Health (AREA)
  • Epidemiology (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • General Chemical & Material Sciences (AREA)
  • Oil, Petroleum & Natural Gas (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Immunology (AREA)
  • Dermatology (AREA)
  • Medicinal Preparation (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Heterocyclic Carbon Compounds Containing A Hetero Ring Having Oxygen Or Sulfur (AREA)
PT128105194T 2012-11-20 2012-12-21 Formulações de acetato de caspofungina PT2922530T (pt)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US201261728406P 2012-11-20 2012-11-20

Publications (1)

Publication Number Publication Date
PT2922530T true PT2922530T (pt) 2016-12-22

Family

ID=47505366

Family Applications (1)

Application Number Title Priority Date Filing Date
PT128105194T PT2922530T (pt) 2012-11-20 2012-12-21 Formulações de acetato de caspofungina

Country Status (15)

Country Link
US (4) US9636407B2 (pt)
EP (1) EP2922530B1 (pt)
CA (1) CA2888625A1 (pt)
CY (1) CY1120016T1 (pt)
DK (1) DK2922530T3 (pt)
ES (1) ES2607646T3 (pt)
HK (1) HK1215668A1 (pt)
HR (1) HRP20161703T1 (pt)
HU (1) HUE032392T2 (pt)
LT (1) LT2922530T (pt)
PL (1) PL2922530T3 (pt)
PT (1) PT2922530T (pt)
SI (1) SI2922530T1 (pt)
SM (1) SMT201600452B (pt)
WO (1) WO2014081443A1 (pt)

Families Citing this family (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2014081443A1 (en) * 2012-11-20 2014-05-30 Fresenius Kabi Usa, Llc Caspofungin acetate formulations
WO2017185030A1 (en) * 2016-04-22 2017-10-26 Fresenius Kabi Usa, Llc Caspofungin formulation with low impurities
EP3768829A4 (en) * 2018-02-01 2022-02-09 The Royal Institution for the Advancement of Learning / McGill University FORMULATIONS TO ENHANCE DELIVERY OF HYDROPHOBIC AGENTS
WO2019157453A1 (en) 2018-02-12 2019-08-15 Trilogy Therapeutics, Inc. Caspofungin compositions for inhalation
CN109758426B (zh) * 2019-01-24 2021-04-27 四川制药制剂有限公司 一种注射用醋酸卡泊芬净药物组合物及其制备方法

Family Cites Families (32)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5378804A (en) * 1993-03-16 1995-01-03 Merck & Co., Inc. Aza cyclohexapeptide compounds
WO1996008266A1 (en) 1994-09-16 1996-03-21 Merck & Co., Inc. Aza cyclohexapeptide compounds
US5516756A (en) 1994-10-31 1996-05-14 Merck & Co., Inc. Aza cyclohexapeptide compounds
US5552521A (en) 1995-02-10 1996-09-03 Merck & Co., Inc. Process for preparing certain aza cyclohexapeptides
US5952300A (en) 1996-04-19 1999-09-14 Merck & Co., Inc. Antifungal compositions
US6069126A (en) 1996-09-12 2000-05-30 Merck & Co., Inc. Antifungal combination therapy
US5936062A (en) 1997-06-12 1999-08-10 Merck & Co., Inc. Process for preparing certain aza cyclohexapeptides
EP1180368B1 (en) 1999-05-31 2007-04-18 Mitsubishi Chemical Corporation Freeze dried hgf preparations
CA2396381A1 (en) 2000-01-20 2001-07-26 Akira Yanagawa Nasally administrable cyclic peptide compositions
US6803046B2 (en) 2002-08-16 2004-10-12 Bracco International B.V. Sincalide formulations
US8158152B2 (en) 2005-11-18 2012-04-17 Scidose Llc Lyophilization process and products obtained thereby
US8232245B2 (en) * 2006-07-26 2012-07-31 Sandoz Ag Caspofungin formulations
TW200826957A (en) 2006-10-16 2008-07-01 Teva Gyogyszergyar Zartkoruen Mukodo Reszvenytarsasag Purification processes for echinocandin-type compounds
WO2009002481A1 (en) 2007-06-26 2008-12-31 Merck & Co., Inc. Lyophilized anti-fungal composition
WO2009006301A2 (en) 2007-06-29 2009-01-08 Battelle Memorial Institute Protein stabilization
CN102026621A (zh) 2008-05-15 2011-04-20 巴克斯特国际公司 稳定的药物制剂
US20090291996A1 (en) 2008-05-21 2009-11-26 Ferenc Korodi Caspofungin free of caspofungin Co
KR20110011704A (ko) 2008-06-25 2011-02-08 테바 기오기스제르갸르 자르트쾨렌 뮈쾨되 레스즈베니타르사사그 카스포펀진 불순물 a를 함유하지 않는 카스포펀진
EP2240507A2 (en) 2008-06-25 2010-10-20 TEVA Gyógyszergyár Zártkörüen Müködö Részvénytársaság Processes for preparing high purity aza cyclohexapeptides
GB0817121D0 (en) 2008-09-18 2008-10-29 Univ St Andrews Anti-fungal therapy
TW201024322A (en) 2008-12-31 2010-07-01 Chunghwa Chemical Synthesis & Biotech Co Ltd Preparation method for nitrogen containing heterocyclic hexapeptide with high conversion rate
US9394340B2 (en) 2009-03-24 2016-07-19 Cadila Healthcare Limited Purification process for lipopeptides
WO2011120842A1 (en) 2010-03-29 2011-10-06 Dsm Ip Assets B.V. Purification of caspofungin intermediates
WO2012038371A1 (en) 2010-09-20 2012-03-29 Xellia Pharmaceuticals Aps Caspofungin composition
CN106397543A (zh) 2010-09-28 2017-02-15 中化帝斯曼制药有限公司荷兰公司 用于分离环六肽的方法
US20140005355A1 (en) 2011-01-03 2014-01-02 Biocon Limited Process for preparation of caspofungin acetate and intermediates
CN102166186A (zh) 2011-04-18 2011-08-31 深圳市健元医药科技有限公司 一种更加稳定的氮杂环己肽类制剂
CN102746384B (zh) 2011-04-22 2016-01-20 上海天伟生物制药有限公司 一种高纯度的卡泊芬净或其盐及其制备方法和用途
RU2592280C2 (ru) 2011-04-28 2016-07-20 Юнитрис Биофарма Ко., Лтд Промежуточное соединение для синтеза каспофунгина и способ его получения
WO2014081443A1 (en) * 2012-11-20 2014-05-30 Fresenius Kabi Usa, Llc Caspofungin acetate formulations
WO2014177483A1 (en) 2013-05-02 2014-11-06 Dsm Sinochem Pharmaceuticals Netherlands B.V. Method for isolating caspofungin
CN105531283A (zh) 2013-09-11 2016-04-27 中化帝斯曼制药有限公司荷兰公司 卡泊芬净衍生物

Also Published As

Publication number Publication date
US20190105392A1 (en) 2019-04-11
EP2922530A1 (en) 2015-09-30
US20170296667A1 (en) 2017-10-19
HK1215668A1 (zh) 2016-09-09
SMT201600452B (it) 2017-01-10
CA2888625A1 (en) 2014-05-30
US9636407B2 (en) 2017-05-02
US20160310597A1 (en) 2016-10-27
SI2922530T1 (sl) 2017-04-26
PL2922530T3 (pl) 2017-04-28
DK2922530T3 (en) 2017-01-09
CY1120016T1 (el) 2018-12-12
HRP20161703T1 (hr) 2017-03-10
HUE032392T2 (en) 2017-09-28
LT2922530T (lt) 2017-01-25
ES2607646T3 (es) 2017-04-03
EP2922530B1 (en) 2016-09-14
WO2014081443A1 (en) 2014-05-30
US20140142032A1 (en) 2014-05-22

Similar Documents

Publication Publication Date Title
HK1216008A1 (zh) 穩定的萬古黴素製劑
ZA201500212B (en) Progesterone formulations
PL3181128T3 (pl) Kompozycja farmaceutyczna nilotynibu
EP2910147A4 (en) CHAIR
AU345839S (en) Chair
EP2910148A4 (en) CHAIR
EP2857033A4 (en) SKIN-PUNKING PEPTIDE
HUE058912T2 (hu) Liposzóma készítmények
EP2812347A4 (en) AUTOPHAGIA-INDUCING PEPTIDE
HK1197193A1 (en) Sunscreen formulations
LT2916871T (lt) Komikronizacijos produktas, apimantis ulipristalio acetatą
EP2861218A4 (en) LIPOSOME FORMULATIONS
HK1215668A1 (zh) 醋酸卡泊芬淨製劑
PT2908835T (pt) Formulações estáveis
HK1203411A1 (en) Inulin and inulin acetate formulations
GB201200555D0 (en) Peptide
HK1209339A1 (en) Pharmaceutical formulations
EP2891663A4 (en) PEPTIDE DERIVED FROM PSF1
GB201219818D0 (en) Chair
GB201206178D0 (en) Formulations
GB201211403D0 (en) Pharmaceutical formulations
GB201211406D0 (en) Pharmaceutical formulations
AU343976S (en) Chair
AU343977S (en) Chair
AU343052S (en) Chair